Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.58 |
| ▸ | CA2 | P00918 | 4/20 | 0.58 |
| ▸ | CA9 | Q16790 | 4/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.58 |
| ▸ | CA7 | P43166 | 3/20 | 0.58 |
| ▸ | HTR2C | P28335 | 4/20 | 0.51 |
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | HTR2B | P41595 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23966139 | 0.90 | HTR2C (0.51) | CA1CA2CA9CA14CA7 | |
| SCHEMBL5520356 | 0.86 | CA1 (0.58) | CA1CA2CA9CA14CA7 | |
| SCHEMBL29670244 | 0.84 | CA1 (0.70) | CA1CA2CA9CA14CA7 | |
| SCHEMBL19453945 | 0.84 | CA1 (0.70) | CA1CA2CA9CA14CA7 | |
| SCHEMBL4242796 | 0.80 | CA1 (0.60) | CA1CA2CA9CA14CA7 | |
| SCHEMBL22701316 | 0.79 | KMT2A (0.49) | CA1CA2CA9CA14CA7 | |
| SCHEMBL22877657 | 0.79 | MAOA (0.60) | KDM1AKMT2AMAOAMEN1 | |
| SCHEMBL4239697 | 0.78 | CA1 (0.53) | CA1CA2CA9CA14CA7 | |
| SCHEMBL5522656 | 0.77 | GID4 (0.69) | CA1CA2CA9CA14CA7 | |
| SCHEMBL19453963 | 0.77 | CA1 (0.60) | CA1CA2CA9CA14CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256201-B2 | Selective estrogen receptor-β ligands | ASTRAZENECA AB (SE) | 2007-08-14 | — | — | US | disclosed |
| US-20050101584-A1 | Selective estrogen receptor-beta ligands | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | US | disclosed |
| EP-1341765-A1 | THERAPEUTIC COMPOUNDS | AstraZeneca AB (SE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002046164-A1 | THERAPEUTIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101584-A1 | Selective estrogen receptor-beta ligands | ESR2, ESRRA, ESRRB | CA1 3708/4885CA2 4743/4885CA9 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.